Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19355669 | MUSCLE-SPECIFIC EXPRESSION CASSETTES | October 2025 | March 2026 | Allow | 5 | 0 | 0 | No | No |
| 19323583 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19300113 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | August 2025 | January 2026 | Allow | 5 | 1 | 0 | No | No |
| 19273982 | POLYPEPTIDE LINKERS FOR USE IN ENGINEERED MEGANUCLEASES | July 2025 | December 2025 | Allow | 5 | 1 | 0 | No | No |
| 19270414 | USE OF G007-LK IN PROMOTING OSTEOGENIC DIFFERENTIATION OF DENTAL MESENCHYMAL STEM CELLS AND BONE TISSUE REGENERATION | July 2025 | November 2025 | Allow | 4 | 0 | 1 | No | No |
| 19268623 | COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION | July 2025 | January 2026 | Allow | 6 | 1 | 0 | Yes | No |
| 19259859 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | July 2025 | February 2026 | Abandon | 7 | 1 | 0 | No | No |
| 19258035 | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | July 2025 | December 2025 | Allow | 5 | 0 | 0 | No | No |
| 19233142 | COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A | June 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19232045 | TYPE V CAS PROTEINS AND APPLICATIONS THEREOF | June 2025 | October 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 19228566 | SYSTEMS AND METHODS FOR REVERSIBLE CRYOPRESERVATION | June 2025 | January 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19227561 | BRAIN ORGANOID CONTAINING OPTIC VESICLES GENERATED BASED ON H9 INDUCTION AND EYE-BRAIN FUSION CULTURE METHOD | June 2025 | February 2026 | Allow | 8 | 1 | 1 | Yes | No |
| 19219917 | COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY DISEASE | May 2025 | March 2026 | Allow | 10 | 2 | 0 | Yes | No |
| 19216307 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | May 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19216250 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | May 2025 | December 2025 | Allow | 7 | 1 | 0 | No | No |
| 19216195 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | May 2025 | January 2026 | Allow | 7 | 1 | 0 | No | No |
| 19214546 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | May 2025 | January 2026 | Allow | 8 | 2 | 0 | No | No |
| 19209618 | ENHANCED OSTEOINDUCTIVE COMPOSITIONS, SYSTEMS, AND METHODS OF MANUFACTURE | May 2025 | March 2026 | Allow | 10 | 1 | 1 | Yes | No |
| 19209435 | COMPOSITIONS AND METHODS FOR TREATMENT | May 2025 | October 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 19200761 | Circular RNA Compositions | May 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19196434 | IDENTIFICATION OF MICRORNA BIOMARKERS FOR DIAGNOSIS AND TREATMENT FOR SLEEP APNEA | May 2025 | October 2025 | Allow | 6 | 0 | 0 | No | No |
| 19194571 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | April 2025 | November 2025 | Allow | 7 | 1 | 0 | No | No |
| 19194480 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | April 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19192918 | GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES | April 2025 | December 2025 | Allow | 8 | 2 | 0 | No | No |
| 19190623 | ALGAL BIOFILM HARVESTING METHOD CAPABLE OF REDUCING RELEASE OF PLANKTONIC MICROALGAE | April 2025 | June 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19188828 | GENE EDITING OF CAR-T CELLS FOR THE TREATMENT OF T CELL MALIGNANCIES WITH CHIMERIC ANTIGEN RECEPTORS | April 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19187919 | METHOD AND SYSTEM FOR IDENTIFYING SMALL MOLECULE BINDERS WITHIN DNA-ENCODED LIBRARY DATASET | April 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19187484 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | April 2025 | November 2025 | Allow | 7 | 1 | 0 | No | No |
| 19184845 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | April 2025 | December 2025 | Allow | 8 | 1 | 0 | No | No |
| 19181736 | METHOD FOR CULTURING PRIMARY CANCER CELLS THROUGH SIMULATED MICROGRAVITY-INDUCED REPROGRAMMING AND APPLICATIONS THEREOF | April 2025 | December 2025 | Allow | 8 | 1 | 1 | No | No |
| 19180809 | REGULATION OF ARTIFICIAL MIRNAS BY ENDOGENOUS TISSUE-SPECIFIC MIRNAS AND METHODS OF USING THE SAME | April 2025 | February 2026 | Abandon | 10 | 1 | 0 | No | No |
| 19171465 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VEN/AZA RESISTANT ACUTE MYELOID LEUKEMIA | April 2025 | June 2025 | Allow | 2 | 0 | 0 | No | No |
| 19170240 | METABOLICALLY OPTIMIZED CELL CULTURE | April 2025 | October 2025 | Allow | 6 | 0 | 0 | No | No |
| 19098197 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS ASSOCIATED WITH INFECTIOUS DISEASE | April 2025 | January 2026 | Allow | 10 | 2 | 1 | No | No |
| 19097114 | AAV CAPSID VARIANTS AND USES THEREOF | April 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19093919 | METHODS FOR PREPARING MESENCHYMAL STEM CELLS | March 2025 | January 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19092326 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | March 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19092703 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 19092639 | APTAMER AND RIBOZYME EQUILIBRIUM SHIFTING (ARES) RNA CIRCUITS AND USES THEREOF | March 2025 | March 2026 | Allow | 11 | 1 | 1 | No | No |
| 19092801 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | March 2025 | October 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19086228 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSION | March 2025 | October 2025 | Allow | 7 | 1 | 2 | Yes | No |
| 19085903 | Compositions and Methods for NK-92 Cells Expressing Native CD16 | March 2025 | March 2026 | Allow | 12 | 2 | 1 | No | No |
| 19083713 | METHOD FOR PREPARING HEMOGENIC ENDOTHELIUM CELL AND METHOD FOR PREPARING HEMATOPOIETIC STEM CELL OR HEMATOPOIETIC STEM AND PROGENITOR CELL | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 19084507 | COMPOSITION AND METHOD FOR INHIBITING ANGIOTENSINOGEN (AGT) PROTEIN EXPRESSION | March 2025 | September 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19083361 | Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using Same | March 2025 | January 2026 | Allow | 10 | 1 | 1 | Yes | No |
| 19077324 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19071148 | Viral Vectors For Treating Neurogenic Detrusor Overactivity | March 2025 | October 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 19070094 | COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A | March 2025 | November 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19070308 | Method and Apparatus for Producing CAR T Cells | March 2025 | November 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 19066066 | EXPRESSION SYSTEM FOR PRODUCT MANUFACTURING | February 2025 | September 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19064383 | NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19061532 | EXTRACTION OF ANTIMETHANOGENIC COMPOUNDS | February 2025 | June 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19060511 | NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS | February 2025 | September 2025 | Allow | 7 | 1 | 1 | No | No |
| 19056056 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19053424 | CULTURE MEDIUM AND METHOD FOR INDUCING IPSC DIFFERENTIATION TO OBTAIN MACROPHAGES AND USE THEREOF | February 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19054630 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19054315 | CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USE | February 2025 | March 2026 | Allow | 13 | 3 | 0 | No | No |
| 19054728 | TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION – UPREGULATION 1 (ACT-UP1) AND USES THEREOF | February 2025 | January 2026 | Allow | 12 | 2 | 1 | No | No |
| 19052052 | Methods and Compositions for Treatment of Polycystic Kidney Disease | February 2025 | November 2025 | Allow | 9 | 1 | 1 | No | No |
| 19050950 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | February 2025 | December 2025 | Allow | 11 | 1 | 0 | No | No |
| 19048826 | LIPID COMPOSITION TARGETING ANTIGEN-PRESENTING CELLS AND USE THEREOF | February 2025 | September 2025 | Allow | 7 | 1 | 0 | No | No |
| 19046845 | METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIA | February 2025 | October 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 19044249 | Epigen AU/11: A NATURAL MATRIX FOR RESTORING HOMEOSTASIS IN CANCER CELL-INFILTRATED TISSUE | February 2025 | July 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 19042264 | PHOSPHATE SENSING MICROBIAL GENE SWITCH | January 2025 | February 2026 | Allow | 12 | 2 | 1 | Yes | No |
| 19043304 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | January 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19042240 | INTEGRATIVE PLASMID | January 2025 | February 2026 | Allow | 12 | 2 | 0 | No | No |
| 19034336 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | January 2025 | December 2025 | Allow | 11 | 2 | 0 | No | No |
| 19029060 | CULTURE MEDIA BASED ON PROTEIN HYDROLYSATE AND A PROCESS FOR PREPARING THEREOF | January 2025 | January 2026 | Allow | 12 | 2 | 0 | Yes | No |
| 19029962 | IONIZABLE CATIONIC LIPIDS | January 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 19026966 | NOVEL AAV CAPSIDS FOR TARGETING NERVOUS SYSTEM AND USES THEREOF | January 2025 | August 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19027181 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | January 2025 | November 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 19028916 | METHODS FOR SEQUENCING SAMPLES | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19028930 | Product, system and method of cell cultivation | January 2025 | December 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 19028692 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | January 2025 | August 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19025996 | METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS | January 2025 | October 2025 | Allow | 9 | 3 | 0 | Yes | No |
| 19023934 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | January 2025 | March 2026 | Allow | 14 | 1 | 0 | Yes | No |
| 19025939 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | January 2025 | November 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18992213 | OPTIMIZED METHOD FOR EXPANSION AND LARGE-SCALE PRODUCTION OF REGULATORY T CELLS (Tregs) | January 2025 | February 2026 | Allow | 13 | 2 | 0 | Yes | No |
| 19011407 | Novel CRISPR-Cas sigma enzyme and system | January 2025 | January 2026 | Allow | 12 | 3 | 0 | No | No |
| 19010571 | SMALL RNA-BASED DRUG, PREPARATION AND USE THEREOF IN PROPHYLAXIS AND/OR TREATMENT OF CARDIOMYOPATHY | January 2025 | September 2025 | Allow | 9 | 2 | 1 | No | No |
| 19008720 | C6'-SUBSTITUTED LOCKED NUCLEIC ACID-MODIFIED CAP ANALOG AND USE THEREOF | January 2025 | August 2025 | Allow | 7 | 1 | 1 | No | No |
| 19007236 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19007278 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | April 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19002832 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | December 2024 | October 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18999456 | TARGETING THE PVR AXIS USING CAR T CELL THERAPY AND COMBINATIONS | December 2024 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18990401 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 18988990 | ULTRA-HIGH-CELL-DENSITY MULTICELLULAR TISSUE LIFTING BIOPRINTING DEVICE ASSISTED BY OBLIQUE INCIDENT BULK WAVE AND PRINTING METHOD THEREFOR | December 2024 | April 2025 | Allow | 4 | 0 | 0 | No | No |
| 18990530 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | December 2024 | October 2025 | Allow | 10 | 1 | 1 | No | No |
| 18988719 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | December 2024 | August 2025 | Allow | 8 | 1 | 0 | No | No |
| 18984398 | METHOD FOR GENERATING GENOME-EDITED CHICKENS | December 2024 | June 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18983137 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18982078 | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell | December 2024 | September 2025 | Allow | 9 | 1 | 1 | No | No |
| 18979415 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | December 2024 | October 2025 | Allow | 11 | 2 | 0 | No | No |
| 18979378 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | December 2024 | December 2025 | Allow | 12 | 2 | 0 | No | No |
| 18977470 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | December 2024 | November 2025 | Allow | 11 | 1 | 0 | No | No |
| 18977518 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | December 2024 | November 2025 | Allow | 11 | 1 | 0 | No | No |
| 18977579 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | December 2024 | October 2025 | Allow | 11 | 1 | 0 | No | No |
| 18873580 | STAGED CULTURE METHOD FOR IN-VITRO EXPANSION OF HUMAN CYTOKINE-INDUCED KILLER (CIK) AND USE THEREOF | December 2024 | August 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18976043 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | December 2024 | January 2026 | Allow | 13 | 1 | 0 | Yes | No |
| 18976118 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | December 2024 | October 2025 | Allow | 11 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1630.
With a 31.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1630 is part of Technology Center 1600. This group has examined 101,912 patent applications in our dataset, with an overall allowance rate of 50.3%. Applications typically reach final disposition in approximately 36 months.
Applications in Group 1630 receive an average of 2.10 office actions before reaching final disposition. The median prosecution time is 36 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.